

Virginia Medicaid
Pharmacy & Therapeutics Committee Meeting
Agenda
600 East Broad Street – 1st Floor Conference Rooms
Richmond, VA 23219
Thursday, April 24, 2025 – 1 PM – 4 PM

Welcome and Comments **Cheryl J. Roberts, J.D. Medicaid Director**

Call to Order **Lisa Stevens Price, MD, Chief Medical Officer, Chair**

Drug Utilization Review (DUR) Board Report **Rachel Cain, PharmD**

Approval of Minutes from January 16, 2025 Meeting **P&T Committee Members**

Old Business **P&T Committee Members**

- **Bylaws**

PDL (PREFERRED DRUG LIST) Management **P&T Committee Members**

PDL Off Cycle – New Drug Review (*Therapeutic Class*)

Brand Drugs

- | | |
|---|--|
| <ul style="list-style-type: none">• Nemluvio (nemolizumab-ilto)• Cobenfy (xanomeline and trospium chloride)• Opipza (aripiprazole)• Alhemo (concizumab-mtci)• Hympavzi (marstacimab-hncq) | <ul style="list-style-type: none">Immunomodulators Atopic Dermatitis (Closed Class)Antipsychotics (Closed Class)Antipsychotics (Closed Class)Hemophilia Treatments (Closed Class)Hemophilia Treatments (Closed Class) |
|---|--|

PDL Quarter 2 – Annual Review: Classes with updates

Analgesics

- Antimigraine Agents
- Antimigraine Agents Other (**Closed Class**)
- Non-Steroidal Anti-Inflammatory Drugs (NSAID) (includes Cox-2 inhibitors and topical agents)
- Opioids: Long Acting
- Opioid Dependency Treatment Agents (**Closed Class**) (includes oral buprenorphine)
- Opioids: Short Acting (includes combination drugs and lozenges)

Antibiotics / Anti-Infectives

- Antifungal (oral)
- Antibiotics (topical)
- Cephalosporins (Second and Third Generations)
- Gastrointestinal
- Ketolides & Macrolides (Adult and Pediatric)
- Quinolones (Second and Third Generations)
- Quinolones (Otic)

Antivirals

- Antivirals for Herpes (HSV)
- Antivirals for Influenza

Cardiac

- Anticoagulants (*includes oral agents, low molecular weight heparins & Factor XA Inhibitors*) (**Closed Class**)

- Platelet Aggregation Inhibitors

Contraceptives

- Long-Acting Reversible Contraceptives (LARCS) (includes long-acting IUDs & injectable)

Dermatologic Agents (Topical)

- Acne Agents (includes benzoyl peroxide, clindamycin, retinoids & combinations)
- Antifungal Agents, Topical
- Psoriasis Agents
- Rosacea Agents

Immunological Agents

- Cytokine & CAM Antagonists with Related Agents including Methotrexate (*all indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis, Cryopyrin-Associated Periodic Syndromes (CAPS)*) (Closed class)

Respiratory

- Immunomodulators, Asthma (Closed class)

PDL Quarter 2 – Annual Review

Therapeutic Classes without Significant Updates (reviewed by the Department)

TBD

Confidential Meeting (Pricing Information Discussion)

P&T Committee Members & DMAS Staff

Criteria Discussion of Off Cycle New Drugs

P&T Committee Members

Criteria Discussion of Quarter 2 Drugs

P&T Committee Members

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Criteria Discussion of GLP-1 RAs for Obstructive Sleep Apnea

P&T Committee Members

Other Business

Chair

Next Meeting – June 26th, 2025 (tentative)

Chair

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on **only** the drug classes in Quarter 2 scheduled for review at the April meeting and new drugs in PDL OFF Cycle listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Quarter 2 Annual Reviews – April 2024 to present.
- Off Cycle New Drugs – April 2023 to present.

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. Speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an

outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send requested information to pdlinput@dmas.virginia.gov and david.damico@primetherapeutics.com by **5 p.m. EST on Thursday, March 13, 2025.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov by **5 p.m. EST Thursday, March 13, 2025.**